青岛威兰生物科技有限公司

公司简介

Qingdao Vland Biotech Inc. is established in 2005 and we have four main businesses including enzymes, probiotics, vaccine and animal health care products. It has 33 subsidiary companies, 12 production bases and 9 technology centers with more than 1500 employees. In 2019, Vland was listed on SSE A-Shares (Stock Code 603739). 

We stays committed to providing core technology support for biological manufacturing, green solutions for food safety and also clean energy-saving technology for traditional industries including agriculture and husbandry, textile, paper making, detergent, food, biofuel, environmental protection, etc. With the philosophy of technological innovation driving development in mind, our research team consists of 34 Ph.Ds and more than 300 high-level talents from worldwide.

We have established cooperative relationship with prestigious universities, institutes and enterprises in more than 60 countries or regions such as the United States, Europe, Russia and Japan. In 2014, JBS-Vland Life Sciences, LLC. was set up in the United States for a globalized R&D network. In 2015, Vland and Evonik started to cooperate in the R&D and manufacture of probiotics. In 2017, Vland-ADM Joint Enzyme R&D Center was built in California, US. In 2018, Vland Biotechnology Ho Chi Minh Company Limited was established in Vietnam. Vland has been maximizing its R&D capabilities and expanding the scope of its biotechnological research for better, safer and healthier products and solutions.